Metabolic assessment of gradual development of moderate experimental colitis in IL-10 deficient mice

Journal of Proteome Research

Volumn 8, Issue 5, 2009, Pages 2376-2387

  Martin, Francois Pierre J ^a   Rezzi, Serge ^a   Montoliu, Ivan ^a   Philippe, David ^a   Tornier, Lionel ^a   Messlik, Anja ^d   Hölzlwimmer, Gabriele ^b   Baur, Pia ^d   Quintanilla Fend, Leticia ^b   Loh, Gunnar ^c   Blaut, Michael ^c   Blum, Stephanie ^a   Kochhar, Sunil ^a   Haller, Dirk ^d  

^a NESTLÉ RESEARCH CENTER   (Switzerland)

^b Institut für Pathologie   (Germany)

^c GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chemometrics; Experimental colitis; Gut dysfunction; IBD; IL 10 deficient mice; Metabonomics; NMR

Indexed keywords

AMYLOID A PROTEIN; CITRIC ACID; GLUCOSE; INTERLEUKIN 10; LACTIC ACID; LOW DENSITY LIPOPROTEIN; POLYUNSATURATED FATTY ACID; PYRUVIC ACID; TUMOR NECROSIS FACTOR RECEPTOR 2; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHEMOMETRICS; COLITIS; CONTROLLED STUDY; ENTERITIS; FATTY ACID OXIDATION; GLYCOLYSIS; HISTOPATHOLOGY; HOMEOSTASIS; MOUSE; MUSCLE ATROPHY; NONHUMAN; PRIORITY JOURNAL; TYPHLITIS;

AMYLOID; ANIMALS; BLOOD GLUCOSE; CECUM; CITRATES; COLITIS; COLON; DISEASE PROGRESSION; FATTY ACIDS, UNSATURATED; INTERLEUKIN-10; LACTATES; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MAGNETIC RESONANCE SPECTROSCOPY; METABOLOME; METABOLOMICS; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; PYRUVATES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TIME FACTORS;

MUS;

EID: 66749130197     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr801006e     Document Type: Article

References (53)

1. Ahmad, T.; Tamboli, C. P.; Jewell, D.; Colombel, J. F. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 2004, 126 (6), 1533-1549.
2. Loftus, E. V., Jr. Inflammatory bowel disease extending its reach. Gastroenterology 2005, 129 (3), 1117-1120.
3. Loftus, E. V., Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004, 126 (6), 1504-1517.
4. Levine, A. D.; Fiocchi, C. Immunology of inflammatory bowel disease. Curr. Opin. Gastroenterol. 2000, 16 (4), 306-309.
5. Werner, T.; Haller, D. Intestinal epithelial cell signalling and chronic inflammation: From the proteome to specific molecular mechanisms. Mutat. Res. 2007, 622 (1-2), 42-57.
6. Hampe, J.; Heymann, K.; Kruis, W.; Raedler, A.; Folsch, U. R.; Schreiber, S. Anticipation in inflammatory bowel disease: a phenomenon caused by an accumulation of confounders. Am. J. Med. Genet. 2000, 92 (3), 178-183.
7. Schreiber, S.; Hampe, J. Genomics and inflammatory bowel disease. Curr. Opin. Gastroenterol. 2000, 16 (4), 297-305.
8. Haller, D. Intestinal epithelial cell signalling and host-derived negative regulators under chronic inflammation: to be or not to be activated determines the balance towards commensal bacteria. Neurogastroenterol. Motil. 2006, 18 (3), 184-199.
9. Swidsinski, A.; Ladhoff, A.; Pernthaler, A.; Swidsinski, S.; Loening- Baucke, V.; Ortner, M.; Weber, J.; Hoffmann, U.; Schreiber, S.; Dietel, M.; Lochs, H. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002, 122 (1), 44-54.
10. Kuhn, R.; Lohler, J.; Rennick, D.; Rajewsky, K.; Muller, W. Inter- leukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75 (2), 263-274.
11. de Waal, M. R.; Abrams, J.; Bennett, B.; Figdor, C. G.; de Vries, J. E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 1991, 174 (5), 1209-1220.
12. Caligiuri, G.; Rudling, M.; Ollivier, V.; Jacob, M. P.; Michel, J. B.; Hansson, G. K.; Nicoletti, A. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apo- lipoprotein E knockout mice. Mol. Med. 2003, 9 (1-2), 10-17.
13. Shkoda, A.; Ruiz, P. A.; Daniel, H.; Kim, S. C.; Rogler, G.; Sartor, R. B.; Haller, D. Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation. Gastroenterology 2007, 132 (1), 190-207.
14. Harper, P. H.; Truelove, S. C.; Lee, E. C.; Kettlewell, M. G.; Jewell, D. P. Split ileostomy and ileocolostomy for Crohn's disease of the colon and ulcerative colitis: a 20 year survey. Gut 1983, 24 (2), 106-113.
15. Duncan, M.; Davison, J. S.; Sharkey, K. A. Review article: endocan- nabinoids and their receptors in the enteric nervous system. Aliment. Pharmacol. Ther. 2005, 22 (8), 667-683.
16. Actis, G. C.; Pazienza, P.; Rosina, F. Mesalamine for inflammatory bowel disease: recent reappraisals. Inflamm. Allergy Drug Targets 2008, 7 (1), 1-5.
17. Siemanowski, B.; Regueiro, M. Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 2007, 10 (3), 178-184.
18. Reid, G.; Jass, J.; Sebulsky, M. T.; McCormick, J. K. Potential uses of probiotics in clinical practice. Clin. Microbiol. Rev. 2003, 16 (4), 658-672.
19. Ahmadi, A. A.; Polyak, S. Endoscopy/surveillance in inflammatory bowel disease. Surg. Clin. North Am. 2007, 87 (3), 743-762.
20. Nicholson, J. K.; Holmes, E.; Lindon, J. C. Metabonomics; Understanding the consequences of xenobiotic induced metabolic dysfunction using NMR spectroscopy of the biofluids, multivariate statistics and expert system. Xenobiotica 1999, 29 (11), 1181-1189.
21. Clayton, T. A.; Lindon, J. C.; Cloarec, O.; Antti, H.; Charuel, C.; Hanton, G.; Provost, J. P.; Le Net, J. L.; Baker, D.; Walley, R. J.; Everett, J. R.; Nicholson, J. K. Pharmaco-metabonomic phenotyp- ing and personalized drug treatment. Nature (London) 2006, 440 (7087), 1073-1077.
22. Balasubramanian, K.; Kumar, S.; Singh, R. R.; Sharma, U.; Ahuja, V.; Makharia, G. K.; Jagannathan, N. R. Metabolism of the colonic mucosa in patients with inflammatory bowel diseases: an in vitro proton magnetic resonance spectroscopy study. Magn Reson. Imaging 2009, 27 (1), 79-86.
23. Rezzi, S.; Ramadan, Z.; Fay, L. B.; Kochhar, S. Nutritional meta- bonomics: applications and perspectives. J. Proteome. Res. 2007, 6 (2), 513-525.
24. Li, M.; Wang, B.; Zhang, M.; Rantalainen, M.; Wang, S.; Zhou, H.; Zhang, Y.; Shen, J.; Pang, X.; Zhang, M.; Wei, H.; Chen, Y.; Lu, H.; Zuo, J.; Su, M.; Qiu, Y.; Jia, W.; Xiao, C.; Smith, L. M.; Yang, S.; Holmes, E.; Tang, H.; Zhao, G.; Nicholson, J. K.; Li, L.; Zhao, L. Symbiotic gut microbes modulate human metabolic phenotypes. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (6), 2117-2122.
25. Rezzi, S.; Ramadan, Z.; Martin, F. P.; Fay, L. B.; Bladeren, P. V.; Lindon, J. C.; Nicholson, J. K.; Kochhar, S. Human metabolic phenotypes link directly to specific dietary preferences in healthy individuals. J. Proteome Res. 2007, 6 (11), 4469-4477.
26. Martin, F.-P. J.; Wang, Y.; Sprenger, N.; Yap, I. K. S.; Rezzi, S.; Ramadan, Z.; Pere-Trepat, E.; Rochat, F.; Cherbut, C.; van Bladeren, P.; Fay, L. B.; Kochhar, S.; Lindon, J. C.; Holmes, E.; Nicholson, J. K. Top-down systems biology integration of conditional prebiotic transgenomic interactions in a humanized microbiome mouse model. Mol. Syst. Biol. 2008, 4 , 205.
27. Werner, T.; Shkoda, A.; Haller, D. Intestinal epithelial cell proteome in IL-10 deficient mice and IL-10 receptor reconstituted epithelial cells: impact on chronic inflammation. J. Proteome Res. 2007, 6 (9), 3691-3704.
28. Katakura, K.; Lee, J.; Rachmilewitz, D.; Li, G.; Eckmann, L.; Raz, E. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J. Clin. Invest. 2005, 115 (3), 695-702.
29. Jeener, J.; Meier, B. H.; Bachmann, P.; Ernst, R. R. Investigation of exchange processes by two-dimensional NMR spectroscopy. J. Chem. Phys. 1979, 71 , 4546-4553.
30. Meiboom, S.; Gill, D. Modified spin-echo method for measuring nuclear relaxation times. Rev. Sci. Instrum. 1958, 29 , 688-691.
31. Wu, D. H.; Chen, A. D.; Johnson, C. S. An improved diffusion- ordered spectroscopy experiment incorporating bipolar-gradient pulses. J. Magn. Res., Ser. A 1995, 115 (2), 260-264.
32. Wold, S.; Esbensen, K.; Geladi, P. Principal Component Analysis. Chemom. Intell. Lab. Syst. 1987, 2 (1-3), 37-52.
33. Scholz, M.; Gatzek, S.; Sterling, A.; Fiehn, O.; Selbig, J. Metabolite fingerprinting: detecting biological features by independent component analysis. Bioinformatics 2004, 20 (15), 2447-2454.
34. Wold, S.; Geladi, P.; Esbensen, K.; Ohman, J. Multi-Way Principal Components and PLS-Analysis. J. Chemom. 1977, 1 , 41-46.
35. Trygg, J.; Wold, S. Orthogonal projections to latent structures (OPLS). J. Chemom. 2002, 16 (3), 119-128.
36. 1H NMR spectroscopic metabonomic studies. Anal. Chem. 2005, 77 (2), 517-526.
37. Martin, F. P.; Verdu, E. F.; Wang, Y.; Dumas, M. E.; Yap, I. K.; Cloarec, O.; Bergonzelli, G. E.; Corthesy-Theulaz, I.; Kochhar, S.; Holmes, E.; Lindon, J. C.; Collins, S. M.; Nicholson, J. K. Transge- nomic metabolic interactions in a mouse disease model: interactions of Trichinella spiralis infection with dietary Lactobacillus paracasei supplementation. J. Proteome Res. 2006, 5 (9), 2185-2193.
38. 13C NMR spectroscopy of human blood plasma. Anal. Chem. 1995, 67 (5), 793-811.
39. 1H NMR data sets. Anal. Chem. 2005, 77 (5), 1282-1289.
40. Denis, M. A.; Reenaers, C.; Fontaine, F.; Belaiche, J.; Louis, E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm. Bowel Dis. 2007, 13 (9), 1100-1105.
41. Cabana, V. G.; Siegel, J. N.; Sabesin, S. M. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J. Lipid Res. 1989, 30 (1), 39-49.
42. Niederau, C.; Backmerhoff, F.; Schumacher, B.; Niederau, C. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology 1997, 44 (13), 90-107.
43. Singh, U. P.; Singh, R.; Singh, S.; Karls, R. K.; Quinn, F. D.; Taub, D. D.; Lillard, J. W., Jr. CXCL10+ T cells and NK cells assist in the recruitment and activation of CXCR3+ and CXCL11+ leukocytes during Mycobacteria-enhanced colitis. BMC. Immunol. 2008, 9, 25.
44. de Villiers, W. J.; Varilek, G. W.; de Beer, F. C.; Guo, J. T.; Kindy, M. S. Increased serum amyloid a levels reflect colitis severity and precede amyloid formation in IL-2 knockout mice. Cytokine 2000, 12 (9), 1337-1347.
45. Singh, U. P.; Singh, S.; Singh, R.; Cong, Y.; Taub, D. D.; Lillard, J. W., Jr. CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J. Interferon Cytokine Res. 2008, 28 (1), 31-33.
46. Rojas-Cartagena, C.; Flores, I.; Appleyard, C. B. Role of tumor necrosis factor receptors in an animal model of acute colitis. Cytokine 2005, 32 (2), 85-93.
47. Chambers, R. E.; Stross, P.; Barry, R. E.; Whicher, J. T. Serum amyloid A protein compared with C-reactive protein, alpha 1-antichymotrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease. Eur. J. Clin. Invest. 1987, 17 (5), 460-467.
48. Lindhorst, E.; Young, D.; Bagshaw, W.; Hyland, M.; Kisilevsky, R. Acute inflammation, acute phase serum amyloid A and cholesterol metabolism in the mouse. Biochim. Biophys. Acta 1997, 1339 (1), 143-154.
49. Getz, G. S.; Reardon, C. A. SAA, HDL biogenesis, and inflammation. J. Lipid Res. 2008, 49 (2), 269-270.
50. Barter, P. The inflammation: lipoprotein cycle. Atheroscler. Suppl. 2005, 6 (2), 15-20.
51. Cheung, M. C.; Brown, B. G.; Marino Larsen, E. K.; Frutkin, A. D.; O'Brien, K. D.; Albers, J. J. Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular disease. Biochim. Biophys. Acta 2006, 1762 (1), 131-137.
52. Calder, P. C. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol. Nutr. Food Res. 2008, 52 (8), 885-897.
53. Cross, R. K.; Wilson, K. T. Nitric oxide in inflammatory bowel disease. Inflamm. Bowel Dis. 2003, 9 (3), 179-189.